UCFA
SRNE

United Capital Financial Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

United Capital Financial Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-26,805
Closed -$299K – 1231
2020
Q3 		$299K Buy
26,805
+13,305
+99% +$122K ﹤0.01% 953
2020
Q2 		$85K Buy
+13,500
New +$51.7K ﹤0.01% 1147

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

United Capital Financial Advisors's SRNE Position: Q4 2020 in Review

United Capital Financial Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2020, closing a stake of 26,805 shares — an estimated $299K sold.

United Capital Financial Advisors first reported a position in SRNE in Q2 2020 and held it in 2 quarters. The position peaked at $299K in Q3 2020. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

  • United Capital Financial Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • United Capital Financial Advisors sold 26,805 Sorrento Therapeutics, Inc. shares in Q4 2020, an estimated $299K.
  • United Capital Financial Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 2 quarters.
  • United Capital Financial Advisors's Sorrento Therapeutics, Inc. position peaked at $299K in Q3 2020.
  • 219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on United Capital Financial Advisors's 13F filing for Q4 2020, filed 17 Feb 2021.